

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

- **GUMCSPDAR** Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
- **MYDBLDF** Daratumumab, Bortezomib, Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma
- **SAAVGEM** Gemcitabine for Advanced Soft Tissue Sarcoma

Expansion of Existing Programs

- **GOEAVDCAT, GOEAVDPNC** Dostarlimab in Combination with Chemotherapy for Endometrial Cancer

Drug Update

Cyclophosphamide 25 mg Tablet Discontinuation

Cancer Drug Manual®

New lazertinib

Revised fulvestrant

Chemotherapy Preparation and Stability Chart aldesleukin, bortezomib, cyclophosphamide, glofitamab, ifosfamide, mirvetuximab soravtansine, pentostatin, tocilizumab

IV Bag Size & Vial Selection mirvetuximab soravtansine

High-Alert Medications pentostatin, ropeginterferon, taletrectinib

Retired ropeginterferon

Continuing Education

FPON Webinar Early Onset Cancer

Benefit Drug List

New GUMCSPDAR, MYDBLDF, SAAVGEM

Revised BRAJPNT, GOEAVDCAT, GOEAVDPNC

Deleted ULKO

Protocols, PPPOs and Patient Handouts

New **GU** GUMCSPDAR **HN** HNAJALPCRT, HNAJALPPRT, HNAJPMB, HNAJPMBCRT, HNAJPMBPRT, HNNAPMB **LU** ULUAVPPAF, ULUAVPPAMI **MY** MYDBLDF **SA** SAAVGEM **Revised** **BR** BRAJCAP, BRAJPNT, BRAJPNCT, BRAJPNCT, BRAVCMPO, BRAVPGC, BRLACPNAC, BRLACPACG, BRLACTWAC, BRLACTWACG, BRPCTAC, BRPCWTAC **CN** CNAJ12TZRT, CNAJ2TZRT, CNELTZRT **GI** GIAJCAPOX, GIAJFFOX, GIAJRALOX, GIAVFIROXB, GIAVRALOX, GICAPOX, GICOXB, GIEFFOXRT, GIFFOXB, GIFFOXPAN, GIFIRINOX, GIFOLFOX, GIGAJCOX, GIGAJFFOX, GIGAVCOX, GIGAVCOXN, GIGAVCOXP, GIGAVCOXT, GIGAVCOXZ, GIGAVFFOX, GIGAVFFOXN, GIGAVFFOXP, GIGAVFFOXT, GIGAVFFOXZ, GIGAVPCOXT, GIGAVPFOXT, GIGFLODOC, GIPAJFIROX, GIPAVFFOX, GIRAJCOX, GIRAJFFOX, GIRNACOX, GIRNAFFOX **GO** GOCXPEMCRRT, GOEAVDCAT, GOEAVDPNC, GOEAVPCAT, GOEAVPPNC, GOENDAVPL, GOENDAVPL6, GOOVCYCPO **GU** GUMCSPABI, GUMCSPAPA, GUMCSPENZ, GUMVAC, UGUNMPDAR, GUOTTIP **LK** ULKO **LU** LUAVATZ, LUAVATZ4 **LY** LYCYCLO, LYDARCBDF, LYGEMOXPEG, LYPOLABR, LYPOLARCHP **MY** MYBLDF, MYBLDPRE, MYBORMTN, MYBORPRE, MYBORREL, MYBSD, MYCARDEX, MYCARLD, MYDARBD, MYDARCBDF, MYDARLD, MYDARLDF, UMYISACARD, UMYISAPOMD, UMYLDF, MYLDREL, MYLENMTN, MYMP, MYMPBOR, UMYPOMDEX, UMYTEC **SC** SCOXXR

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 May 2026. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Genitourinary

Darolutamide for Metastatic Castration-Sensitive Prostate Cancer (GUMCSPDAR) – The BC Cancer Genitourinary Tumour Group is implementing darolutamide as another treatment option for patients with metastatic castration-sensitive prostate cancer (mCSPC). Androgen deprivation therapy (ADT) (GUPADT)

Editor's Choice

should be maintained, except in patients with prior bilateral orchiectomy. Patients with mCSPC are eligible to receive treatment with either abiraterone (GUMCSPABI), apalutamide (GUMCSPAPA), darolutamide (GUMCSPDAR), darolutamide with docetaxel (UGUMCSPDD) or enzalutamide (GUMCSPENZ), but not their sequential use.

The randomized, placebo-controlled phase III ARANOTE trial demonstrated that the addition of darolutamide to ADT improved radiographic progression-free survival in patients with mCSPC.^{1,2} Adverse events were similar in the two groups; the incidence of fatigue was lower in the darolutamide group.

Myeloma

Daratumumab, Bortezomib, Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma (MYDBLDF) – The BC Cancer Myeloma Tumour Group is introducing a new treatment program for patients with newly diagnosed, transplant-eligible multiple myeloma. Daratumumab is used in addition to the standard frontline approach of bortezomib, lenalidomide and dexamethasone in the induction phase; following transplant and consolidation, daratumumab and lenalidomide are continued in the maintenance phase.

The randomized active-controlled phase III PERSEUS trial investigated the addition of daratumumab to standard of care in this patient population.^{3,4} Daratumumab improved progression-free survival, complete response rate, and the rate of minimal residual disease (MRD) negativity. Grade 3 or 4 adverse events occurred in most patients in both groups, the most common being neutropenia, thrombocytopenia and diarrhea.

Sarcoma

Gemcitabine for Advanced Soft Tissue Sarcoma (SAAVGEM) – The BC Cancer Sarcoma Tumour Group is introducing single-agent gemcitabine for patients with advanced soft tissue sarcoma who are not fit for doublet therapy with gemcitabine and docetaxel (SAAVGEMD). Despite being well enough for systemic therapy, frail patients may not be able to tolerate doublet therapy. Evidence indicates that gemcitabine is active across many soft tissue sarcoma subtypes, and that it represents a single-agent treatment option for frail patients.^{5,6}

References:

1. Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. *J Clin Oncol* 2024;42(36):4271-4281. <https://doi.org/10.1200/JCO-24-01798>
2. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Darolutamide (Nubeqa®). *Canadian Journal of Health Technologies* 2025;5(11):1-10. <https://doi.org/10.51731/cjht.2025.1283>
3. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med* 2023;390(4):301-13. <https://doi.org/10.1056/NEJMoa2312054>
4. Canada's Drug Agency (CDA-AMC). Reimbursement Recommendation. Daratumumab (Darzalex SC®). *Canadian Journal of Health Technologies* 2025;5(5):1-37. <https://doi.org/10.51731/cjht.2025.1130>
5. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. *Cancer Chemother Pharmacol* 2000;45:177-181. <https://doi.org/10.1007/s002800050027>
6. Maki RG, Wathen JK, Shreyaskumar RP, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. *J Clin Oncol* 2007;25(19):2755-2763. <https://doi.org/10.1200/JCO.2006.10.4117>

Editor's Choice

Expansion of Existing Programs

BC Cancer Provincial Systemic Therapy has approved the expansion of the following treatment programs effective 01 May 2026.

Gynecologic Oncology

Dostarlimab in Combination with Chemotherapy for Endometrial Cancer (GOEAVDCAT, GOEAVDPNC) –

The BC Cancer Gynecologic Oncology Tumour Group is expanding the eligibility criteria for dostarlimab in combination with carboplatin-paclitaxel for patients with primary advanced/recurrent endometrial cancer. These programs are no longer restricted to patients with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) tumours. In the second interim analysis of the RUBY trial in patients with advanced/recurrent endometrial cancer, the addition of dostarlimab to chemotherapy improved OS in the overall study population; this population included both MSI-H/dMMR and microsatellite stable/mismatch repair-proficient tumours.¹

References:

1. Powell MA, Bjørge L, Willmott L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. *Ann Oncol* 2024;35(8):728-738.

<https://doi.org/10.1016/j.annonc.2024.05.546>

Drug Update

Cyclophosphamide 25 mg Tablet Discontinuation

The cyclophosphamide 25 mg tablet has been discontinued by the manufacturer. Remaining supply at BC Cancer is due to expire 31 May 2026. The cyclophosphamide 50 mg tablet continues to be available but should not be split. As such, applicable treatment protocols, provincial preprinted orders and Cerner PowerPlans have been updated to reflect rounding to the nearest 50 mg, rather than to the nearest 25 mg.

Cancer Drug Manual[©]

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Lazertinib Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Jenny Ko (medical oncologist, BC Cancer Lung Tumour Group) and Jelena Mucovic (tumour group pharmacist representative, BC Cancer Provincial Pharmacy). Lazertinib is a third generation, orally administered EGFR inhibitor. It is used in combination with amivantamab in the treatment of non-small cell lung cancers harbouring an EGFR mutation. The usual dose is 240 mg once daily.

Highlights from these documents include:

- moisturizers, sunscreen and topical/oral antibiotics are recommended to prevent skin and nail toxicities
- anticoagulant prophylaxis is recommended to prevent venous thromboembolism
- ocular toxicity is reported; patients with worsening eye symptoms should avoid contact lens use

Lazertinib has been added to the **Auxiliary Label List** and evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Fulvestrant Monograph and Patient Handout

Supply and Storage: added Formative brand; deleted AstraZeneca and Teva brands

Patient Handout: updated storage bullet

Chemotherapy Preparation and Stability Chart

Aldesleukin

Deleted SteriMax brand (manufacturer for SteriMax brand previously updated to Iovance/Bioscript)

Bortezomib

Vial stability: updated with extended stability information for Taro/Sun Pharma brand

Product stability: updated with extended stability information for Taro/Sun Pharma brand

Cyclophosphamide

Added new brands: Andone and Marcan (Canadian marketed brands); Seacross UK and Sandoz USA (temporary importation for drug shortage)

Glofitamab

Updated preparation instructions for 10 mg dose and recommended bag size

Ifosfamide

Deleted Baxter USA brand

Mirvetuximab soravtansine

Deleted SAP supply (AbbVie EU)

Product: updated preparation instructions and final product information per marketed product information

Special Precautions: updated per current product information (non-DEHP bag/tubing no longer required)

Pentostatin

Noted Hospira/Pfizer USA brand as SAP supply

Product: updated final concentration

Tocilizumab

Added Celltrion biosimilar brand

Product stability: updated for Roche brand

IV Bag Size & Vial Selection

Mirvetuximab soravtansine has been updated on the [IV Bag Size & Vial Selection](#) table.

Oncology High-Alert Medications

Pentostatin and **taletrectinib** have been added to, and **ropeginterferon alfa-2b** has been removed from, the [Oncology High-Alert Medications](#) list.

Retired Documents

The **Roppeginterferon Interim Monograph** has been retired as ropeginterferon alfa-2b is no longer available in Canada. Health Canada had authorized its temporary importation in early 2025 to mitigate peginterferon alfa-2b supply constraints.

Continuing Education

Family Practice Oncology Network | Webinar: Early Onset Cancer

The Family Practice Oncology Network (FPON) is pleased to announce **Early Onset Cancer**, a webinar with Dr. Arkhjamil Angeles. The webinar is Thursday 21 May 2026, from 0800-0900h, as part of the accredited, complimentary FPON webcasts.

By the end of the session, participants will be able to:

- Summarize the epidemiology and trends of early onset cancer (EOC)
- Review differences between EOC and later onset cancers
- Cite potential risk factors for EOC
- Integrate clinical considerations for patients with EOC

For more information and link to registration, visit:

[FPON Webinar | Early Onset Cancer | UBC CPD](#)

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 May 2026:

Protocol Title	Protocol Code	Benefit Status
Treatment of Metastatic Castration-Sensitive Prostate Cancer using Darolutamide	GUMCSPDAR	Class I
Treatment of Previously Untreated Multiple Myeloma and Eligible for Stem Cell Transplant using Daratumumab, Bortezomib, Lenalidomide and Dexamethasone	MYDBLDF	Class I
Treatment of Advanced Soft Tissue Sarcoma using Gemcitabine	SAAVGEM	Class I

Revised Programs

The following treatment programs have been revised on the BC Cancer [Benefit Drug List](#) effective 01 May 2026:

Protocol Title	Protocol Code	Benefit Status
Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB and Trastuzumab	BRAJPNT	Class I
Treatment of Microsatellite Instability-High or Mismatch Repair-Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel	GOEAVDCAT	Class I
Alternative Treatment of Microsatellite Instability-High or Mismatch Repair-Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin	GOEAVDPNC	Class I

Deleted Programs

The following treatment program has been deleted from the BC Cancer [Benefit Drug List](#) effective 01 May 2026:

Protocol Title	Protocol Code	Benefit Status
Interim Protocol for Ropeginterferon Alfa-2b Therapy of Chronic Myeloid Neoplasms and Hypereosinophilic Syndrome ➤ Previously reimbursable during peginterferon alfa-2a shortage	ULK0	Restricted

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts *(new documents checked ☑)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUMCSPDAR	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Darolutamide	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
HNAJALPCRT	Adjuvant Treatment Squamous Cell Carcinoma of the Head and Neck using Pembrolizumab and Concurrent Weekly Carboplatin and Radiation	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
HNAJALPPRT	Alternative Adjuvant Treatment of Squamous Cell Carcinoma of the Head and Neck using Pembrolizumab and Concurrent Cisplatin and Radiation	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
HNAJPMB	Adjuvant Treatment of Squamous Cell Carcinoma of the Head and Neck using Pembrolizumab	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
HNAJPMBCRT	Adjuvant Treatment of Squamous Cell Carcinoma of the Head and Neck using Pembrolizumab and Concurrent 3-Weekly Carboplatin and Radiation	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
HNAJPMBPRT	Adjuvant Treatment of Squamous Cell Carcinoma of the Head and Neck using Pembrolizumab and Concurrent Cisplatin and Radiation Therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
HNNAPMB	Neoadjuvant Treatment of Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
ULUAVPPAF	Advanced treatment of Non-Small Cell Lung Cancer with Carboplatin, Pemetrexed and Amivantamab	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
ULUAVPPAMI	Treatment of Advanced Non-Small Cell Lung Cancer with Carboplatin, Pemetrexed and Amivantamab	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
MYDBLDF	Treatment of Previously Untreated Multiple Myeloma and Eligible for Stem Cell Transplant using Daratumumab, Bortezomib, Lenalidomide and Dexamethasone	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> 4 x PPPOs	<input type="checkbox"/>
SAAVGEM	Treatment of Advanced Soft Tissue Sarcoma using Gemcitabine	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJCAP	Therapy of Adjuvant Breast Cancer using Capecitabine	<i>Eligibility and contact information updated</i>	---	---
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB, Carboplatin and Trastuzumab	<i>Cockcroft-Gault equation clarified</i>	---	---
BRAJPNT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB and Trastuzumab	<i>Protocol title updated</i>	---	<i>Protocol title, uses and side effects updated</i>
BRAVCMPO	Palliative Therapy for Metastatic Breast Cancer using Metronomic Low-Dose Oral Cyclophosphamide and Methotrexate	<i>Eligibility and exclusions clarified; contact information, tests and dose modifications updated</i>	<i>Dose reduction updated; treatment and tests clarified</i>	---
BRAVPGC	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine and Carboplatin	<i>Cockcroft-Gault equation clarified</i>	---	---
BRLACPNAC	Alternative Neoadjuvant Therapy for Triple-Negative Breast Cancer using Carboplatin and Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	<i>Cockcroft-Gault equation clarified</i>	---	---
BRLACPNACG	Alternative Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Paclitaxel NAB Followed by Doxorubicin and Cyclophosphamide	<i>Cockcroft-Gault equation clarified</i>	---	---
BRLACTWAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Contact information updated; eligibility, exclusions, Cockcroft-Gault equation and units of measure clarified</i>	<i>Units of measure clarified</i>	---
BRLACTWACG	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Contact information updated; eligibility, exclusions, Cockcroft-Gault equation, tests and units of measure clarified</i>	<i>Tests and units of measure clarified</i>	---
BRPCTAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Pembrolizumab with Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Cockcroft-Gault equation clarified</i>	---	---
BRPCWTAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Pembrolizumab, Weekly Carboplatin and Weekly Paclitaxel, Followed by Doxorubicin and Cyclophosphamide	<i>Cockcroft-Gault equation clarified</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
CN Neuro-Oncology				
CNAJ12TZRT	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Temozolomide timing clarified</i>	<i>Temozolomide timing clarified</i>	<i>Timing clarified</i>
CNAJ TZRT	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Temozolomide timing clarified</i>	<i>Temozolomide timing clarified</i>	<i>Timing clarified</i>
CNELTZRT	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy	<i>Temozolomide timing clarified</i>	<i>Temozolomide timing clarified</i>	<i>Timing clarified</i>
GI Gastrointestinal				
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin and Capecitabine	<i>SCOXRX reference removed</i>	---	---
GIAJFFOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; contact information clarified</i>	<i>Reformatted</i>	---
GIAJRALOX	Adjuvant Combination Chemotherapy for Node-Positive Colon Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>SCOXRX reference removed</i>	---	---
GIAVFIROXB	Palliative Treatment of Metastatic Colorectal Cancer using Irinotecan, Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab	<i>SCOXRX reference removed; units of measure clarified</i>	<i>Units of measure clarified</i>	---
GIAVRALOX	Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine	<i>SCOXRX reference removed; contact information clarified</i>	---	---
GICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Oxaliplatin and Capecitabine	<i>SCOXRX reference removed; contact information clarified</i>	---	---
GICOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Bevacizumab and Capecitabine	<i>SCOXRX reference removed; contact information clarified</i>	---	---
GIEFFOXRT	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Radiation Therapy	<i>SCOXRX reference removed; dose banding and contact information updated</i>	<i>Dose banding updated</i>	---
GIFFOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab	<i>SCOXRX reference removed; contact information clarified</i>	---	---
GIFFOXPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Panitumumab	<i>SCOXRX reference removed; contact information clarified</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIFIRINOX	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; units of measure clarified; contact information updated</i>	<i>Units of measure clarified</i>	---
GIFOLFOX	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>SCOXRX reference removed; contact information updated</i>	<i>Reformatted</i>	---
GIGAJCOX	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node-Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin and Capecitabine	<i>SCOXRX reference removed; contact information updated</i>	---	---
GIGAJFFOX	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node-Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; contact information updated</i>	<i>Reformatted</i>	---
GIGAVCOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin	<i>SCOXRX reference removed; contact information updated</i>	---	---
GIGAVCOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	<i>SCOXRX reference removed; contact information updated</i>	---	---
GIGAVCOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	<i>SCOXRX reference removed</i>	---	---
GIGAVCOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Trastuzumab	<i>SCOXRX reference removed</i>	---	---
GIGAVCOXZ	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Zolbetuximab	<i>SCOXRX reference removed</i>	---	---
GIGAVFFOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; contact information updated</i>	<i>Reformatted</i>	---
GIGAVFFOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	<i>SCOXRX reference removed; contact information updated</i>	---	---
GIGAVFFOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	<i>SCOXRX reference removed</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIGAVFFOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>SCOXRX reference removed</i>	<i>Spelling corrected</i>	---
GIGAVFFOXZ	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction (GEJ) or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Zolbetuximab	<i>SCOXRX reference removed</i>	---	---
GIGAVPCOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab	<i>SCOXRX reference removed</i>	---	---
GIGAVPFOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>SCOXRX reference removed</i>	---	---
GIGFLODOC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Docetaxel, Oxaliplatin, Infusional Fluorouracil and Leucovorin	<i>SCOXRX reference removed; units of measure and contact information clarified</i>	<i>Units of measure clarified</i>	---
GIPAJFIROX	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; units of measure and contact information clarified</i>	<i>Units of measure clarified</i>	---
GIPAVFFOX	Palliative Combination Chemotherapy for Metastatic Pancreatic or Biliary Tract Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; contact information updated</i>	<i>Reformatted</i>	---
GIRAJCOX	Adjuvant Treatment for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	<i>SCOXRX reference removed; contact information updated</i>	---	---
GIRAJFFOX	Adjuvant Treatment for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; contact information updated</i>	---	---
GIRNACOX	Neoadjuvant Treatment for Locally Advanced Rectal Cancer using Oxaliplatin and Capecitabine	<i>SCOXRX reference removed</i>	---	---
GIRNAFFOX	Neoadjuvant Treatment for Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>SCOXRX reference removed; contact information updated</i>	---	---
GO Gynecologic Oncology				
GOCXPEMCRT	Treatment of Locally Advanced Cervical Cancer with Pembrolizumab, Cisplatin and Radiation Therapy	---	<i>Follow-up orders updated</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOEAVDCAT	Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel	<i>Protocol title and eligibility updated</i>	---	---
GOEAVDPNC	Alternative Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin	<i>Protocol title and eligibility updated</i>	---	---
GOEAVPCAT	Treatment of Advanced or Recurrent Endometrial Cancer using Carboplatin, Paclitaxel and Pembrolizumab	<i>Eligibility note and treatment duration updated</i>	---	---
GOEAVPPNC	Alternative Treatment of Advanced or Recurrent Endometrial Cancer using Pembrolizumab, Paclitaxel NAB and Carboplatin	<i>Eligibility note updated; treatment duration clarified</i>	---	---
GOENDAVPL	Treatment of Endometrial Cancer with Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib	<i>Exclusion criteria updated</i>	---	---
GOENDAVPL6	Treatment of Endometrial Cancer with Microsatellite Stability or Mismatch Repair Proficiency using 6-Weekly Pembrolizumab and Lenvatinib	<i>Exclusion criteria updated</i>	---	---
GOOVCYCPO	Palliative Therapy for Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Metronomic Low-Dose Oral Cyclophosphamide	<i>Eligibility, exclusions and tests clarified; contact information updated</i>	<i>Tests and treatment updated</i>	---
GU Genitourinary				
GUMCSPABI	Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone	<i>Eligibility and contact information updated</i>	---	---
GUMCSPAPA	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Apalutamide	<i>Eligibility updated</i>	---	---
GUMCSPENZ	Treatment for Metastatic Castration-Sensitive Prostate Cancer using Enzalutamide	<i>Eligibility updated</i>	---	---
GUMVAC	Therapy for Transitional Cell Cancers of the Urothelium using Methotrexate, Vinblastine, Doxorubicin and Cisplatin	<i>Eligibility, exclusions, dose modifications, precautions, units of measure and Cockcroft-Gault equation clarified</i>	<i>Tests and units of measure clarified</i>	---
UGUNMPDAR	Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Darolutamide	<i>Tests updated</i>	---	---
GUOTTIP	Neoadjuvant Therapy for Penile Squamous Cell Carcinoma Using Paclitaxel, Ifosfamide and Cisplatin (TIP)	<i>Cockcroft-Gault equation clarified</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LK Leukemia/BMT				
ULK0	Interim Protocol for Ropeginterferon Alfa-2b Therapy of Chronic Myeloid Neoplasms and Hypereosinophilic Syndrome	<i>Protocol deleted</i>	<i>PPPO deleted</i>	---
LU Lung				
LUA VATZ	Treatment of Advanced Non-Small Cell Lung Cancer using Atezolizumab	---	---	<i>Treatment, side effects and contact information updated</i>
LUA VATZ4	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Atezolizumab	---	---	<i>Treatment, side effects and contact information updated</i>
LY Lymphoma				
LYCYCLO	Therapy of Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma using Cyclophosphamide	<i>Eligibility, exclusions and units of measure clarified; treatment and contact information updated</i>	<i>Treatment updated</i>	---
LYDARCBDF	Treatment of Previously Untreated Light Chain Amyloidosis and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	<i>Tests, supportive medications and premedications updated</i>	<i>Tests, treatment and daratumumab premedications updated</i>	<i>Additional medications updated</i>
LYGEMOXPEG	Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	<i>SCOXRX reference removed; contact information updated; exclusions, premedications, precautions and units of measure clarified</i>	<i>Premedications updated; tests and units of measure clarified</i>	---
LYPOLABR	Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab	<i>Treatment updated</i>	<i>Treatment updated</i>	---
LYPOLARCHP	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Prednisone, Rituximab and Polatuzumab Vedotin	<i>Precautions updated</i>	---	---
MY Myeloma				
MYBLDF	Treatment of Multiple Myeloma using Bortezomib, Lenalidomide and Dexamethasone	<i>Tests updated</i>	<i>Tests updated</i>	<i>Additional medications updated</i>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
MYBLDPRE	Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	---
MYBORMTN	Maintenance Therapy of Multiple Myeloma using Bortezomib for Patients with the High-Risk Chromosome Abnormality	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	---
MYBORPRE	Treatment of Multiple Myeloma using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	---
MYBORREL	Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone with or without Cyclophosphamide	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	---
MYBSD	Treatment of Multiple Myeloma using Bortezomib, Selinexor and Dexamethasone with or without Cyclophosphamide	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	<i>Treatment updated</i>
MYCARDEX	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	<i>Treatment and side effects updated</i>
MYCARLD	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide and Dexamethasone	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	<i>Treatment updated; side effects clarified</i>
MYDARBD	Treatment of Multiple Myeloma Using Daratumumab, Bortezomib and Dexamethasone	<i>Tests, supportive medications and premedications updated</i>	IV Cycle 1 PPPO <i>Tests and treatment updated</i> IV Cycle 2+ and SC PPPOs <i>Tests, treatment and premedications updated</i>	<i>Treatment and additional medications updated</i>
MYDARCBDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	<i>Tests, supportive medications and premedications updated</i>	IV Cycle 1 PPPO <i>Tests and treatment updated</i> IV Cycle 2+ and SC PPPOs <i>Tests, treatment and premedications updated</i>	---
MYDARLD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone with or without Cyclophosphamide	<i>Tests, supportive medications and premedications updated</i>	IV Cycle 1 PPPO <i>Tests and treatment updated</i> IV Cycle 2+ and SC PPPOs <i>Tests, treatment and premedications updated</i>	<i>Additional medications, treatment and side effects updated; interactions clarified</i>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
MYDARLDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	<i>Tests, supportive medications and premedications updated</i>	IV Cycle 1 PPPO <i>Tests and treatment updated</i> IV Cycle 2+ and SC PPPOs <i>Tests, treatment and premedications updated</i>	---
UMYISACARD	Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Tests and supportive medications updated</i>	Cycle 1 and Cycle 2+ PPPOs <i>Tests and treatment updated</i>	---
UMYISAPOMD	Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide	<i>Tests and supportive medications updated</i>	Cycle 1 and Cycle 2+ PPPOs <i>Tests and treatment updated</i>	---
UMYLDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Lenalidomide with Low-Dose Dexamethasone	<i>Tests updated</i>	<i>Tests and treatment updated</i>	---
MYLDREL	Therapy of Relapsed Multiple Myeloma using Lenalidomide with Dexamethasone	<i>Tests updated</i>	<i>Tests and treatment updated</i>	---
MYLENMTN	Maintenance Therapy of Multiple Myeloma using Lenalidomide	<i>Tests updated</i>	<i>Tests and treatment updated</i>	---
MYMP	Treatment of Multiple Myeloma using Melphalan and Prednisone	<i>Tests updated</i>	<i>Tests updated</i>	---
MYMPBOR	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan	<i>Tests and supportive medications updated</i>	<i>Tests and treatment updated</i>	---
UMYPOMDEX	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone	<i>Tests updated</i>	<i>Tests and treatment updated</i>	---
UMYTEC	Treatment of Relapsed and Refractory Multiple Myeloma using Teclistamab	<i>Tests and supportive medications updated</i>	Cycle 1 Inpatient, Cycle 1 Outpatient and Cycle 2+ PPPOs <i>Tests and premedications updated</i>	---
SC Supportive Care				
SCOXRX	Inpatient Protocol Summary for Oxaliplatin Desensitization	<i>Protocol deleted</i>	---	---

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor	604-877-6275	druginfo@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Network	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@phsa.ca ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
Jelena Mucovic, BScPharm (Assistant Editor)
Mário de Lemos, PharmD, MSc(Oncol)
Jeevan Dosanjh, RN, BScN, MN

Alina Gerrie, MD, MPH, FRCPC
Alison Pow, BScPharm
Yuna Jang, RN